Appointment of Non-Executive Director

26 Jul 2018

London, UK, 26 July 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, with an initial focus on addressing iron deficiency, is pleased to announce the appointment of Hans-Peter Hasler as a NonExecutive Director of the Company with immediate effect.

You can read the full press release here

Back to news